Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030

Quante, Anne S.; Ming, Chang; Rottmann, Miriam; Engel, Jutta; Boeck, Stefan; Heinemann, Volker; Westphalen, C. Benedikt; Strauch, Konstantin

doi:10.1002/cam4.767

Cited by 225 publications

(164 citation statements)

References 18 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…1,2 The vast majority of patients are diagnosed with advanced disease and do not qualify for potentially curative resection. Despite minor advances using intensified chemotherapeutic regimens like FOLFIRINOX and gemcitabine plus nab-paclitaxel, prognosis in advanced PC remains dire with a median overall survival (OS) of less than 1 y.…”

Section: Introductionmentioning

confidence: 99%

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Up to now, the efficacy of programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade in pancreatic cancer (PC) remains uncertain. Serum levels of soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have been reported to be independent prognostic factors in solid tumors susceptible to checkpoint blockade. Provenience, regulation and immunologic function of sPD-1 and sPD-L1 in cancer are poorly understood. To the best of our knowledge, sPD-1 and sPD-L1 have not been measured conjointly in any cancer type yet.In contrast to other tumor entities, sPD-1/sPD-L1 levels did not indicate an adverse outcome in a cohort of 41 patients with advanced PC. We observed a close positive correlation of sPD-L1 levels with sPD-1 in patients with advanced PC, suggesting a common provenience and regulation of sPD-1 and sPD-L1 in cancer patients. Higher sPD-L1 levels were present in patients with elevated C-reactive protein or strong tumoral T cell infiltration, while no correlation of sPD-L1 levels with tumoral PD-L1 expression was found. Our findings indicate that sPD-1 and sPD-L1 are markers of systemic inflammation in (pancreatic) cancer. In a subset of PC patients, elevation in sPD-L1 levels might be caused by an inflammatory tumor typeindependent of tumoral PD-L1 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a median overall survival of about 6 months and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030 [1,2]. It is therefore one of the most lethal cancers, as indicated by a very high mortality-toincidence ratio [3].…”

Section: Introductionmentioning

confidence: 99%

Oligometastatic Disease in Pancreatic Cancer - How to Proceed

Renz

Boeck²,

Roeder

et al. 2017

Visc Med

Self Cite

View full text Add to dashboard Cite

Background: Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or ablative treatment options for advanced-stage disease. However, highly selected patients suffering from synchronous and metachronous oligometastatic PDAC may potentially benefit from a surgical resection with an acceptable morbidity. Methods: This review summarizes and discusses the current literature on the management of oligometastatic disease regarding PDAC, focusing on para-aortic lymph nodes as well as isolated hepatic and pulmonary metastases. Results and Conclusion: In order to further investigate the feasibility and efficacy of such an approach, a prospective multicenter trial, in which survival and quality of life after metastatic resection and systemic chemotherapy is evaluated, has to be initiated. Additionally, local and locoregional ablation techniques or stereotactic body radiation therapy as therapeutic options for isolated metastases in PDAC need further research in order to determine their significance and benefit.

show abstract

“…In the United States, PDA is the fourth leading cause of cancer-associated deaths [3], and by the year 2030, it is expected to become the second leading cause of cancer-related deaths globally [4,5]. Late diagnosis and resistance to conventional therapy contributes to the lethality of this disease [6].…”

Section: Introductionmentioning

confidence: 99%

Targeting reactive oxygen species in development and progression of pancreatic cancer

Durand

Störz

2016

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Introduction Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis. Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA. To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by additional up-regulation of antioxidant systems. Areas Covered We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biological consequences of ROS in PDA. Additionally, we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention. An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Expert Commentary Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult. The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies. These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.

show abstract

Projections of cancer incidence and cancer‐related deaths in Germany by 2020 and 2030

Cited by 225 publications

References 18 publications

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

Oligometastatic Disease in Pancreatic Cancer - How to Proceed

Targeting reactive oxygen species in development and progression of pancreatic cancer

Contact Info

Product

Resources

About